Metropolis Healt

Q1 FY27Healthcare Services

Metropolis Healt Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹567

Market cap₹11.6K Cr

P/E55.5

Updated25 Aug 2026

Read3 min read

What the Q1 FY27 call signalled

2 of 3 strong

RevenueRank 3

MarginRank 1

CapexYes

Not discussed on this call: fundraise, order book.

The short version

Metropolis expects a medium-term compounded annual growth rate (CAGR) of 14%-15% in revenue. Management remains extremely optimistic about FY 2026-2027 growth and margin expansion.

From Metropolis Healt's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3

Metropolis expects a medium-term compounded annual growth rate (CAGR) of 14%-15% in revenue.
Patient volume growth is projected at 9%-10%, driven by network expansion into Tier-2 and Tier-3 towns and improved productivity of existing centers.
Network expansion continues with plans to add over 500 centers in the current financial year, deepening presence in 750 towns.
Balanced growth seen across mature centers and ramp-up in new centers.
B2C and B2B segments both contributing healthily, with B2C revenue growing 18% and B2B growing 15% year-on-year in Q1 FY 2027.
Growth supported by increased test volumes (+11% YoY), richer product mix, and improved realizations.
The company remains optimistic about broad-based and structural growth momentum across geographies, channels, and test categories.

Profitability & Margins

Management remains extremely optimistic about FY 2026-2027 growth and margin expansion.
Target to bring Core Diagnostics' EBITDA margin to 25% within 3-4 years; currently at ~8%.
TruHealth portfolio already aligned with company-level margins, contributing accretively to EBITDA.
Organic revenue growth guidance maintained at 14%-15% CAGR over medium term, largely driven by volume growth (9%-10%) and product mix.
EBITDA margin expected to expand by 100-150 basis points in the current financial year.
Medium-term target EBITDA margin is 27%-28% supported by operating leverage, productivity improvements, and cost optimization.
Strategy includes disciplined inorganic growth via value-accretive acquisitions.
Profit After Tax (PAT) grew 26% YoY in Q1 FY27; margins expanded by 90 bps to 12.6%.
Overall, sustainable, profitable growth with continued EBITDA and earnings expansion anticipated over the medium term.

See what Metropolis Healt said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

- Last year, Metropolis Healthcare spent around INR 65 crores on CAPEX for the entire Group, including acquired entities. - CAPEX for the current year is expected to be in similar lines, i.e., approximately INR 65 crores. - The Company is deepening presence in existing 750 towns rather than expanding beyond, limiting additional cost pressures. - Lab expansion agenda has been on hold for the last five quarters, avoiding extra CAPEX from new labs. - The focus remains on increasing productivity and operating leverage in existing centers. - Strategic investments continue in bolt-on acquisitions with strong consumer brand, ethical practices, and positive unit economics—focused on disciplined valuations and accretive deals. - Larger acquisitions may be considered if EPS accretive and value accretive to shareholders. Overall, CAPEX is moderate and focused on operational efficiencies, network deepening, and selective strategic acquisitions.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any current or future plans for fundraising through debt or equity in the provided text.
The management emphasizes organic growth and disciplined inorganic growth via strategic acquisitions at the right valuations.
The focus is on margin expansion, operational efficiency, and integrating recent acquisitions rather than raising new capital.
CAPEX for the current year is expected to be around INR 65 crores, similar to the prior year, funded from internal resources.
The company is cautious about acquisitions, focusing on earnings accretive deals and maintaining a disciplined valuation approach.

See what Metropolis Healt said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The document provided does not mention any information regarding Current or Expected Orderbook or Pending Orders for Metropolis Healthcare Limited.

Metropolis Healt — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Metropolis Healthcare Ltd's management said in earlier quarters

Others in Healthcare Services this season

Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Health X Platform Ltd (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare Institute Ltd vs Manipal Health Enterprises Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Metropolis Healt Q1 FY27 results?

Metropolis expects a medium-term compounded annual growth rate (CAGR) of 14%-15% in revenue. Management remains extremely optimistic about FY 2026-2027 growth and margin expansion.

What is Metropolis Healt share price analysis?

Metropolis Healt currently shows a below-average growth signal. The stock trades at a P/E of 55.5 with a market cap of ₹11,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Metropolis Healt planning capital expenditure?

Last year, Metropolis Healthcare spent around INR 65 crores on CAPEX for the entire Group, including acquired entities.

Keep Metropolis Healt on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.